These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22038317)

  • 21. L44. Management of relapses in vasculitis.
    Mouthon L
    Presse Med; 2013 Apr; 42(4 Pt 2):619-22. PubMed ID: 23477710
    [No Abstract]   [Full Text] [Related]  

  • 22. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).
    Graves JE; Nunley K; Heffernan MP
    J Am Acad Dermatol; 2007 Jan; 56(1):e55-79. PubMed ID: 17190618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological therapy for systemic vasculitis: a systematic review.
    Silva-Fernández L; Loza E; Martínez-Taboada VM; Blanco R; Rúa-Figueroa I; Pego-Reigosa JM; Muñoz-Fernández S;
    Semin Arthritis Rheum; 2014 Feb; 43(4):542-57. PubMed ID: 23978781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
    Hoffman GS
    Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
    [No Abstract]   [Full Text] [Related]  

  • 25. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
    Guerry MJ; Brogan P; Bruce IN; D'Cruz DP; Harper L; Luqmani R; Pusey CD; Salama AD; Scott DG; Savage CO; Watts RA; Jayne DR
    Rheumatology (Oxford); 2012 Apr; 51(4):634-43. PubMed ID: 21613248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Nossent JC
    N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083400
    [No Abstract]   [Full Text] [Related]  

  • 27. Update on the treatment of ANCA associated vasculitis.
    Smith RM
    Presse Med; 2015 Jun; 44(6 Pt 2):e241-9. PubMed ID: 26021670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological therapies: new treatment options for ANCA-associated vasculitis?
    Aries PM; Lamprecht P; Gross WL
    Expert Opin Biol Ther; 2007 Apr; 7(4):521-33. PubMed ID: 17373903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
    Tesar V; Hruskova Z
    Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An overview of pharmacotherapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Stasi R
    Drugs Today (Barc); 2010 Dec; 46(12):919-28. PubMed ID: 21589949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis.
    Furuta S; Jayne D
    Curr Opin Rheumatol; 2014 Jan; 26(1):1-6. PubMed ID: 24276087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
    Ntatsaki E; Carruthers D; Chakravarty K; D'Cruz D; Harper L; Jayne D; Luqmani R; Mills J; Mooney J; Venning M; Watts RA;
    Rheumatology (Oxford); 2014 Dec; 53(12):2306-9. PubMed ID: 24729399
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of vasculitis].
    Novak S
    Reumatizam; 2013; 60(2):47-54. PubMed ID: 24979997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ANCA-associated renal vasculitis - an update.
    Tesar V; Hruskova Z
    Contrib Nephrol; 2013; 181():216-28. PubMed ID: 23689583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in ANCA-associated disease.
    Falk RJ; Jennette JC
    N Engl J Med; 2010 Jul; 363(3):285-6. PubMed ID: 20647204
    [No Abstract]   [Full Text] [Related]  

  • 39. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
    Alba MA; Flores-Suárez LF
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Karassa FB
    N Engl J Med; 2010 Nov; 363(21):2073; author reply 2073-4. PubMed ID: 21083398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.